WHITEHAWK THERAPEUTICS, INC. Research and Development Expense
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Research and Development Expense of $12.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $12.89M, a 73.58% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $17.23M, a 96.09% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $19.02M, a 32.58% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $14.35M, a 43.49% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for fiscal 2025 was $90.96M, a 78.25% increase from fiscal 2024.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for fiscal 2024 was $51.03M, a 4.29% increase from fiscal 2023.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for fiscal 2023 was $48.93M, a 49.80% increase from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. research and development expense for fiscal 2022 was $32.66M, a 66.05% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.89M 10-Q · filed 2026-08-06 | $30.13M 10-Q · filed 2026-08-06 | $49.15M derived: sum of 3 quarters · filed 2026-08-06 | $63.49M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $17.23M 10-Q · filed 2026-05-07 | $36.25M derived: sum of 2 quarters · filed 2026-05-07 | $50.60M derived: sum of 3 quarters · filed 2026-05-07 | $99.41M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $19.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $33.37M derived: sum of 2 quarters · filed 2026-03-12 | $82.17M derived: sum of 3 quarters · filed 2026-08-06 | $90.96M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $14.35M 10-Q · filed 2025-11-06 | $63.15M derived: sum of 2 quarters · filed 2026-08-06 | $71.94M 10-Q · filed 2025-11-06 | $86.29M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $48.81M 10-Q · filed 2026-08-06 | $57.60M 10-Q · filed 2026-08-06 | $71.94M derived: sum of 3 quarters · filed 2026-08-06 | $81.94M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $8.79M 10-Q · filed 2026-05-07 | $23.14M derived: sum of 2 quarters · filed 2026-05-07 | $33.13M derived: sum of 3 quarters · filed 2026-05-07 | $46.23M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $14.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $24.34M derived: sum of 2 quarters · filed 2026-03-12 | $37.44M derived: sum of 3 quarters · filed 2026-03-12 | $51.03M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $10.00M 10-Q · filed 2025-11-06 | $23.09M derived: sum of 2 quarters · filed 2025-11-06 | $36.68M 10-Q · filed 2025-11-06 | $49.45M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $13.09M 10-Q · filed 2025-08-07 | $26.69M 10-Q · filed 2025-08-07 | $39.45M derived: sum of 3 quarters · filed 2025-08-07 | $51.34M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $13.59M 10-Q · filed 2025-05-08 | $26.36M derived: sum of 2 quarters · filed 2025-05-08 | $38.25M derived: sum of 3 quarters · filed 2025-05-08 | $51.57M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $12.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $24.66M derived: sum of 2 quarters · filed 2025-03-28 | $37.97M derived: sum of 3 quarters · filed 2025-03-28 | $48.93M 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | $11.89M 10-Q · filed 2024-11-06 | $25.20M derived: sum of 2 quarters · filed 2024-11-06 | $36.16M 10-Q · filed 2024-11-06 | $45.53M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $13.31M 10-Q · filed 2024-08-07 | $24.27M 10-Q · filed 2024-08-07 | $33.64M derived: sum of 3 quarters · filed 2024-08-07 | $42.41M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $10.96M 10-Q · filed 2024-05-08 | $20.33M derived: sum of 2 quarters · filed 2024-05-08 | $29.10M derived: sum of 3 quarters · filed 2024-05-08 | $36.83M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $18.14M derived: sum of 2 quarters · filed 2024-03-13 | $25.87M derived: sum of 3 quarters · filed 2024-03-13 | $32.66M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $8.77M 10-Q · filed 2023-11-08 | $16.50M derived: sum of 2 quarters · filed 2023-11-08 | $23.29M 10-Q · filed 2023-11-08 | $30.52M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $7.73M 10-Q · filed 2023-08-09 | $14.52M 10-Q · filed 2023-08-09 | $21.75M derived: sum of 3 quarters · filed 2023-08-09 | $27.50M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $6.79M 10-Q · filed 2023-05-10 | $14.02M derived: sum of 2 quarters · filed 2023-05-10 | $19.77M derived: sum of 3 quarters · filed 2023-05-10 | $22.82M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $12.98M derived: sum of 2 quarters · filed 2023-03-29 | $16.03M derived: sum of 3 quarters · filed 2023-03-29 | $19.67M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $5.75M 10-Q · filed 2022-11-09 | $8.80M derived: sum of 2 quarters · filed 2022-11-09 | $12.44M 10-Q · filed 2022-11-09 | $17.77M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $3.04M 10-Q · filed 2022-08-10 | $719.64K 10-Q · filed 2021-08-11 | $6.69M 10-Q · filed 2022-08-10 | $2.95M 10-Q · filed 2021-08-11 | $12.01M derived: sum of 3 quarters · filed 2022-08-10 | $14.41M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $3.64M 10-Q · filed 2022-05-12 | $2.23M 10-Q · filed 2021-05-17 | $8.97M derived: sum of 2 quarters · filed 2022-05-12 | $11.36M derived: sum of 3 quarters · filed 2022-05-12 | $14.91M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $7.72M derived: sum of 2 quarters · filed 2022-03-17 | $11.27M derived: sum of 3 quarters · filed 2022-03-17 | $15.01M 10-K · filed 2022-03-17 | $12.59M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $2.40M 10-Q · filed 2021-11-10 | $3.99M 10-Q · filed 2020-11-10 | $5.94M derived: sum of 2 quarters · filed 2021-11-10 | $9.68M 10-Q · filed 2021-11-10 | $9.36M 10-Q · filed 2020-11-10 | $9.90M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $3.55M 10-Q · filed 2021-08-11 | $5.38M 10-Q · filed 2021-08-11 | $7.51M derived: sum of 3 quarters · filed 2021-08-11 | $10.35M derived: sum of 4 quarters · filed 2021-08-11 | ||||
| 2020-03-31 | $1.83M 10-Q · filed 2021-05-17 | $3.96M derived: sum of 2 quarters · filed 2021-05-17 | $6.80M derived: sum of 3 quarters · filed 2021-05-17 | $9.07M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $4.97M derived: sum of 2 quarters · filed 2021-03-11 | $7.24M derived: sum of 3 quarters · filed 2021-03-11 | $12.82M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $2.84M 10-Q · filed 2020-11-10 | $5.11M derived: sum of 2 quarters · filed 2020-11-10 | $10.70M 10-Q · filed 2020-11-10 | $15.94M derived: sum of 4 quarters · filed 2020-11-10 | ||||
| 2019-06-30 | $2.26M 10-Q · filed 2020-08-12 | $7.85M 10-Q · filed 2020-08-12 | $13.10M derived: sum of 3 quarters · filed 2020-08-12 | $17.45M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | $5.59M 10-Q · filed 2020-05-07 | $10.83M derived: sum of 2 quarters · filed 2020-05-07 | $15.18M derived: sum of 3 quarters · filed 2020-05-07 | $19.41M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $9.60M derived: sum of 2 quarters · filed 2020-03-16 | $13.82M derived: sum of 3 quarters · filed 2020-03-16 | $17.85M 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $4.35M 10-Q · filed 2019-11-07 | $8.58M derived: sum of 2 quarters · filed 2019-11-07 | $12.60M 10-Q · filed 2019-11-07 | $16.38M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $4.23M 10-Q · filed 2019-08-08 | $8.26M 10-Q · filed 2019-08-08 | $12.04M derived: sum of 3 quarters · filed 2019-08-08 | $14.98M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $4.03M 10-Q · filed 2019-05-09 | $7.81M derived: sum of 2 quarters · filed 2019-05-09 | $10.75M derived: sum of 3 quarters · filed 2019-05-09 | $13.92M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $6.72M derived: sum of 2 quarters · filed 2019-03-07 | $9.89M derived: sum of 3 quarters · filed 2019-03-07 | $12.15M 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | $2.94M 10-Q · filed 2018-11-07 | $6.11M derived: sum of 2 quarters · filed 2018-11-07 | $8.37M 10-Q · filed 2018-11-07 | $10.36M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-06-30 | $3.17M 10-Q · filed 2018-08-14 | $5.42M 10-Q · filed 2018-08-14 | $7.42M derived: sum of 3 quarters · filed 2018-08-14 | $10.90M derived: sum of 4 quarters · filed 2018-08-14 | ||||
| 2017-03-31 | $2.26M 10-Q · filed 2018-05-15 | $4.25M derived: sum of 2 quarters · filed 2018-05-15 | $7.73M derived: sum of 3 quarters · filed 2018-05-15 | $10.63M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $5.47M derived: sum of 2 quarters · filed 2018-03-15 | $8.38M derived: sum of 3 quarters · filed 2018-03-15 | $11.37M 10-K · filed 2018-03-15 | ||||
| 2016-09-30 | $3.48M 10-Q · filed 2017-11-13 | $6.38M derived: sum of 2 quarters · filed 2017-11-13 | $9.37M 10-Q · filed 2017-11-13 | |||||
| 2016-06-30 | $2.90M 10-Q · filed 2017-08-10 | $5.89M 10-Q · filed 2017-08-10 | ||||||
| 2016-03-31 | $2.99M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |